What Is GHK-Cu? (Discovery & Age-Related Decline)
In the 1970s, biochemist Dr. Loren Pickart noticed that when liver tissue from older patients was incubated in blood plasma from younger donors, the aged cells began synthesizing proteins like younger tissue again. Tracing the active factor in human plasma led to the isolation of a tiny three-amino-acid peptide: glycyl-L-histidyl-L-lysine (GHK), which exhibits a remarkably high spontaneous affinity for divalent copper ions (Cu²⁺).
Endogenous GHK-Cu is naturally present in human plasma, saliva, and extracellular matrix tissue, where it is released during tissue injury to coordinate repair. However, circulating levels decline significantly with age—dropping by more than 50% by age 60—alongside slower cutaneous wound closure, thinner dermal collagen bundles, and reduced hair follicle vitality.
How GHK-Cu Works: Four Documented Cellular Mechanisms
| Biological Pathway | Molecular Mechanism | Published Evidence Tier |
|---|---|---|
| 1. Copper Delivery & Antioxidant Enzyme Support | Transfers bioavailable Cu²⁺ directly to copper-dependent enzymes involved in cross-linking collagen and elastin fibrils and neutralizing free radicals via superoxide dismutase. | Human dermal biopsies & in vitro fibroblast cultures |
| 2. Balanced Extracellular Matrix Remodeling | Research reports accelerated wound closure and improved quality of healed tissue (PMC4453375). | Human clinical topical & wound-healing studies |
| 3. Transcriptomic Gene Modulation | Influences over 4,000 human genes, upregulating genes associated with tissue repair and antioxidant defense while downregulating genes linked to inflammation and tissue destruction. | Gene expression analyses (PMC3583892) |
| 4. Follicular & Microvascular Support | Supports dermal papilla fibroblast vitality, prolongs the active anagen growth phase, enlarges hair follicle size, and promotes scalp microcirculation (PMC4345932). | Follicular biology & topical scalp studies |
What Dermatology and Wound-Repair Research Shows
Unlike many investigational peptides that have only been tested in rodents, topical GHK-Cu has been studied across human dermatology, wound healing, and follicular research:
- Collagen, Elastin, and Dermal Firmness: Clinical reports describe improvements in skin firmness, elasticity and wrinkles. Separately, gene-expression studies examine GHK-Cu and age-related transcriptional patterns (PMC3583892).
- Wound Closure and Tissue Remodeling: Research published in peer-reviewed wound-care literature shows that GHK-Cu accelerates wound closure, supports angiogenesis in healing skin, and improves the structural organization of newly deposited extracellular matrix (PMC4453375).
- Hair Follicle Vitality: In trichology research, copper tripeptide complexes have been studied for supporting hair follicle size and anagen-phase signaling (PMC4345932).
Safety Considerations & Regulatory Status (April 2026)
Regulatory treatment and safety considerations for GHK-Cu depend strongly on its route of administration and individual skin or health factors:
- Topical Cosmetic Use vs. Unapproved Injection: Under the INCI name Copper Tripeptide-1, GHK-Cu is a legal, widely used cosmetic ingredient in facial serums, eye creams, and scalp formulations. By contrast, injectable GHK-Cu is an unapproved drug product that has not been evaluated by the FDA for systemic safety, sterility, or clinical efficacy.
- Injectable Compounding Status (Withdrawn): On the U.S. FDA's Section 503A Bulk Drug Substances list current as of April 22, 2026, GHK-Cu (for injectable routes) was nominated for Category 2, and that nomination was subsequently withdrawn. Because it does not appear on Category 1 and holds no FDA NDA approval, state-licensed 503A pharmacies cannot compound injectable GHK-Cu for human use.
- Copper Allergy & Very Sensitive Skin: Even with topical cosmetic products, known copper allergy or metal hypersensitivity raises safety concerns for GHK-Cu formulations, and people with very sensitive or barrier-impaired skin can experience localized redness, stinging, or irritation.
- Pregnancy, Breastfeeding & Oncology Cautions: Human developmental safety data are lacking for injectable or systemic GHK-Cu during pregnancy and breastfeeding, and individuals with active cancer or suspicious skin lesions should consult a physician before using growth-factor or tissue-remodeling compounds.
- Analytical & Formulation Considerations: In topical or laboratory formulations, strong chelating agents or concentrated low-pH acids can destabilize the copper(II) coordination complex; GHK-Cu is most stable at a slightly acidic-to-neutral pH around 5.5.
Topical Copper Tripeptide-1 is an established cosmetic ingredient—though anyone with a copper allergy or very sensitive skin should exercise caution—whereas injectable GHK-Cu is not FDA-approved for human use and is excluded during pregnancy and breastfeeding.